Acilog Biopen 100 U/ ML


Acilog Biopen 100 U/ ML


Stock Status:

In Stock

  • *Upload Prescription

    • (max file size 80 MB)



Protamine Crystallised Insulin Aspart



Protamine Crystallized Insulin Aspart is an insulin analog used to improve blood sugar control in diabetic patients.



The main activity of insulin aspart is to regulate glucose metabolism. Insulin aspart binds to insulin receptors in muscle and fat cells and lowers blood sugar by promoting glucose uptake by cells while inhibiting glucose production in the liver.



Insulin Aspart has a faster onset and a shorter duration of action than soluble human insulin. Due to the faster onset of action, Insulin Aspart should generally be given immediately before a meal. When necessary Insulin Aspart may be given soon after a meal.

Dosage of Insulin Aspart is individual and determined on the basis of the physician’s advice in accordance with the needs of the patient. It should normally be used in combination with long-acting insulin given at least once a day.

The individual insulin requirement is usually between 0.5 and 1.0 IU/kg/day in adults and children over 2 years of age. In a meal-related treatment 50-70% of this requirement may be provided by Insulin Aspart and the remainder by long-acting insulin. Adjustment of dosage may also be necessary if patients undertake increased physical activity or change their usual diet. Exercise taken immediately after a meal may increase the risk of hypoglycaemia.

Subcutaneous Injection: Insulin Aspart should be administered by subcutaneous injection in the abdominal region, buttocks, thigh, or upper arm. Because Insulin Aspart has a more rapid onset and a shorter duration of activity than human regular insulin, it should be injected immediately (within 5-10 minutes) before a meal Continuous Subcutaneous Insulin Infusion (CSII) by External Pump Insulin Aspart can also be infused subcutaneously by an external insulin pump. The initial programming of the external insulin infusion pump should be based on the total daily insulin dose of the previous regimen. Approximately 50% of the total dose is usually given as meal-related boluses of Insulin Aspart and the remainder is given as a basal infusion. When used with an infusion pump Insulin Aspart should not be mixed with any other insulin.

Intravenous Use: Insulin Aspart can be administered intravenously under medical supervision for glycemic control with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia. For intravenous use, Insulin Aspart should be used at concentrations from 0.05 IU/mL to 1.0 IU/mL insulin aspart in infusion systems using polypropylene infusion bags. Insulin Aspart has been shown to be stable in infusion fluids such as 0.9% sodium chloride.



Instructions to be given to the patient before injecting this Insulin:

  • According to the instruction given with ConviPen, insert the cartridge into the pen correctly & equip the needle
  • Gently turn the pen upside down for 8-10 times until the insulin in the cartridge becomes uniformly mixed suspension
  • Remove the needle cap, discharge air bubbles in the catridge
  • Adjust the dosage button to get correct dose & inject to the specific site
  • In order to avoid cross contamination, do not let the needle touch anything during the process of preparation.



Several drugs affect glucose metabolism, and dosage adjustments may be required.

The following substances may reduce the demand for insulin and insulin aspart: oral antidiabetic products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, propoxyphene, Pentoxifylline, salicylate and sulfa antibiotics.

The following substances may increase the demand for insulin and insulin aspart: thiazides, glucocorticoids, thyroid hormones, beta sympathomimetic, growth hormone, and danazol. Beta blockers, clonidine, lithium salts and alcohol can enhance or weaken the blood sugar lowering effect of insulin.


Side Effects

The side effects of insulin aspart are hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, itching and rash.


Pregnancy & Lactation

Pregnancy category B. There are no restrictions on the use of protamine crystallized insulin aspart during breastfeeding. Insulin therapy for nursing mothers should not affect the baby. However, the dose may need to be adjusted.


Precautions & Warnings

Dose adjustment and monitoring: Blood glucose should be monitored in all patients treated with insulin. Insulin regimens should be modified cautiously and only under medical supervision


Therapeutic Class

Rapid Acting Insulin


Storage Conditions

Store at 2°C to 8°C in a refrigerator. Do not freeze. Protect from light.


Pharmaceutical Name

ACI Limited